Author: Tomasoni, Daniela; Italia, Leonardo; Adamo, Marianna; Inciardi, Riccardo M.; Lombardi, Carlo M.; Solomon, Scott D.; Metra, Marco
Title: COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease Cord-id: 17hyh3n5 Document date: 2020_5_15
ID: 17hyh3n5
Snippet: Patients with cardiovascular disease and, namely, heart failure are more susceptible to coronavirus disease 2019 (COVIDâ€19) and have a more severe clinical course once infected. Heart failure and myocardial damage, shown by increased troponin plasma levels, occur in at least 10% of patients hospitalized for COVIDâ€19 with higher percentages, 25%–35% or more, when patients critically ill or with concomitant cardiac disease are considered. Myocardial injury may be elicited by multiple mechani
Document: Patients with cardiovascular disease and, namely, heart failure are more susceptible to coronavirus disease 2019 (COVIDâ€19) and have a more severe clinical course once infected. Heart failure and myocardial damage, shown by increased troponin plasma levels, occur in at least 10% of patients hospitalized for COVIDâ€19 with higher percentages, 25%–35% or more, when patients critically ill or with concomitant cardiac disease are considered. Myocardial injury may be elicited by multiple mechanisms, including those occurring with all severe infections, such as fever, tachycardia, adrenergic stimulation, as well as those caused by the exaggerated inflammatory response, endotheliitis and, in some cases, myocarditis that have been shown in patients with COVIDâ€19. A key role may be that of the renin–angiotensinâ€aldosterone system. Severe acute respiratory syndrome coronavirus 2 (SARSâ€CoVâ€2) infects human cells binding to angiotensinâ€convertingâ€enzyme 2 (ACE2), an enzyme responsible of the cleavage of angiotensin II into angiotensin 1–7, which has vasodilating and antiâ€inflammatory effects. Virusâ€mediated downregulation of ACE2 may increase angiotensin II stimulation and contribute to the deleterious hyperâ€inflammatory reaction of COVIDâ€19. On the other hand, ACE2 may be upregulated in patients with cardiac disease and treated with ACE inhibitors or angiotensin receptor blockers. ACE2 upregulation may increase the susceptibility to COVIDâ€19 but may be also protective versus angiotensin II mediated vasoconstriction and inflammatory activation. Recent data show the lack of untoward effects of ACE inhibitors or angiotensin receptor blockers for COVIDâ€19 infection and severity. Prospective trials are needed to ascertain whether these drugs may have protective effects. This article is protected by copyright. All rights reserved.
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date